Humacyte, Inc. HUMA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Humacyte, Inc. (HUMA) is a healthcare company listed in the US with a market value of about $155M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of -$95M, a net margin of -3955.1%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -264%.
About Humacyte
Humacyte is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 0 of the last 6 years in our data. Its share count rose by 53% over three years (dilution for shareholders). It spends 3400% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $2M | $2M | $0 | — | — | — | — |
| Net income | -$95M | -$41M | -$149M | -$111M | -$12M | -$26M | -$67M |
| Free cash flow | -$89M | -$106M | -$100M | -$76M | -$72M | -$81M | -$56M |
| EPS (diluted) | $-0.34 | $-0.26 | $-1.26 | $-1.07 | $-0.12 | $-0.66 | $-11.54 |
| Net margin | -3955.1% | -2003.6% | — | — | — | — | — |
| ROIC | — | -280.5% | -800.8% | -149.8% | -45.3% | -42.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Humacyte pay a dividend?
Not currently.
Is Humacyte a good stock to buy?
We do not give buy or sell advice. Humacyte scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.